MaSTherCell Announces New Commercial Manufacturing Facility for Cell and Gene Therapies
Belgium-based CDMO MaSTherCell will expand its European manufacturing capacity for cell and gene therapy products by setting up a new facility in Belgium.
MaSTherCell SA, a subsidiary of Masthercell Global Inc., a cell and gene therapy-dedicated contract development and manufacturing organization (CDMO), announced in a March 26, 2019 press release that it has signed a lease agreement for a 5700-m2(61,354-ft2) facility located in Belgium. The new facility will become a state-of-the-art manufacturing and production site designed for late-stage and commercially approved cell and gene therapy products. The commercial facility is expected to be operational in early 2021.
This new site will expand the company’s current European manufacturing capacity. The facility will include industry 4.0 precepts such as software integration, intelligent equipment, and integrated processes. MaSTherCell will continue to use its existing site for both industrialization and early to mid-stage clinical programs.
“MaSTherCell has a role to play in solving the current lack of commercial manufacturing capacities in Europe, and we believe this facility will be a game changer for market access worldwide,” said Dr. Denis Bedoret, CEO of MaSTherCell SA and president of Masthercell Global, in the press release.
Setting up the new plant in the Gosselies Biopark will keep the production close to its current site. The plant will create several hundred jobs, said Eric Mathieu, chief of operations of MaStherCell SA, in the press release.
Source: Masthercell
